PE05272003A1 - Pharmaceutical formulation with delayed release that contains 3- (3-dimethylamino-1-ethyl-2-methylpropyl) phenol or a pharmaceutically acceptable salt thereof and tablets for oral administration which contain - Google Patents

Pharmaceutical formulation with delayed release that contains 3- (3-dimethylamino-1-ethyl-2-methylpropyl) phenol or a pharmaceutically acceptable salt thereof and tablets for oral administration which contain

Info

Publication number
PE05272003A1
PE05272003A1 PE2002001030A PE0010302002A PE05272003A1 PE 05272003 A1 PE05272003 A1 PE 05272003A1 PE 2002001030 A PE2002001030 A PE 2002001030A PE 0010302002 A PE0010302002 A PE 0010302002A PE 05272003 A1 PE05272003 A1 PE 05272003A1
Authority
PE
Peru
Prior art keywords
methylpropyl
dimethylamino
phenol
ethyl
contains
Prior art date
Application number
PE2002001030A
Other languages
Spanish (es)
Inventor
Johannes Bartholomaus
Iris Ziegler
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to DE2001152469 priority Critical patent/DE10152469A1/en
Priority to DE2002148309 priority patent/DE10248309A1/en
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of PE05272003A1 publication Critical patent/PE05272003A1/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26010444&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE05272003(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Abstract

DONDE DICHA FORMULACION SE ENCUENTRA EN UNA MATRIZ CON LIBERACION RETARDADA DE SUSTANCIA ACTIVA, LA CUAL CONTIENE 1% A 80% DE UNO O VARIOS POLIMEROS HIDROFILOS O HIDROFOBOS COMO FORMADORES DE MATRIZ FARMACEUTICAMENTE ACEPTABLES Y QUE PRESENTA IN VITRO UNA VELOCIDAD DE LIBERACION MEDIDA CON APLICACION DEL METODO PADDLE pH. Wherein said formulation IS IN A MATRIX WITH RELEASE DELAYED active substance, which contains 1% to 80% of one or more hydrophilic or hydrophobic and matrix forming pharmaceutically acceptable POLYMERS AND POSING IN VITRO a release rate MEASURE IMPLEMENTATION OF METHOD PADDLE pH. Eur. DE 75 REVOLUCIONES/min EN UN TAMPON A pH 6,8 A 37 °C CON DETECCION ESPECTROMETRICA UV. Eur. DE 75 rev / min in a buffer at pH 6.8 at 37 ° C UV spectrometric detection. TENIENDO LOS SIGUIENTES PORCENTAJES DE LIBERACION DE 3-(3-DIMETILAMINO-1-ETIL-2-METIL-PROPIL) FENOL, MEDIDOS EN RELACION AL 100% DEL PESO DE LA SUSTANCIA ACTIVA : a)DE 3% A 35% DESPUES DE 0,5 h; BEARING THE FOLLOWING PERCENTAGES LIBERATION 3- (3-dimethylamino-1-ethyl-2-methylpropyl) -phenol, measured relative to 100% by weight of the active substance: a) from 3% to 35% after 0 5 h; b)5% A 50% DESPUES DE 1 h; b) 5% to 50% after 1 h; c)10% A 75% DESPUES DE 2 h; c) 10% to 75% after 2 h; d)15% A 82% DESPUES DE 3 h; d) 15% to 82% after 3 h; e)39% A 97% DESPUES DE 6 h; e) 39% to 97% after 6 h; f)MAS DE 50% DESPUES DE 12 h; f) More than 50% after 12 h; g)MAS DE 70% DESPUES DE 18 h; g) over 70% after 18 h; h)MAS DE 80% DESPUES DE 24 h h) more than 80% after 24 h
PE2002001030A 2001-10-24 2002-10-18 Pharmaceutical formulation with delayed release that contains 3- (3-dimethylamino-1-ethyl-2-methylpropyl) phenol or a pharmaceutically acceptable salt thereof and tablets for oral administration which contain PE05272003A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE2001152469 DE10152469A1 (en) 2001-10-24 2001-10-24 Delayed release analgesic formulations, comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol in hydrophilic or hydrophobic polymer matrix
DE2002148309 DE10248309A1 (en) 2002-10-16 2002-10-16 Delayed release analgesic formulations, comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol in hydrophilic or hydrophobic polymer matrix

Publications (1)

Publication Number Publication Date
PE05272003A1 true PE05272003A1 (en) 2003-07-26

Family

ID=26010444

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002001030A PE05272003A1 (en) 2001-10-24 2002-10-18 Pharmaceutical formulation with delayed release that contains 3- (3-dimethylamino-1-ethyl-2-methylpropyl) phenol or a pharmaceutically acceptable salt thereof and tablets for oral administration which contain

Country Status (27)

Country Link
US (6) US20050058706A1 (en)
EP (1) EP1439829B1 (en)
JP (2) JP4758064B2 (en)
KR (1) KR100958045B1 (en)
CN (1) CN100402021C (en)
AR (1) AR036943A1 (en)
AT (1) AT303802T (en)
BR (1) BR0213653A (en)
CA (1) CA2464578C (en)
CO (1) CO5570662A2 (en)
DE (1) DE50204198D1 (en)
DK (1) DK1439829T3 (en)
EC (1) ECSP045102A (en)
ES (1) ES2248622T3 (en)
HK (1) HK1068539A1 (en)
HU (1) HU230161B1 (en)
IL (2) IL161587D0 (en)
MX (1) MXPA04003742A (en)
MY (1) MY127797A (en)
NO (2) NO331896B1 (en)
NZ (1) NZ532999A (en)
PE (1) PE05272003A1 (en)
PL (1) PL216535B1 (en)
PT (1) PT1439829E (en)
SI (1) SI1439829T1 (en)
WO (2) WO2003035054A1 (en)
ZA (1) ZA200403928B (en)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
EP1839654B9 (en) 2002-11-22 2012-01-11 Grünenthal GmbH Use of (1R, 2R)-3-(3-dimenthyl amino-1-ethyl-2-methyl-propyl) phenol for treating inflammatory pain
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE10336400A1 (en) 2003-08-06 2005-03-24 Grünenthal GmbH Abuse-proofed dosage form
SI1842533T1 (en) * 2003-08-06 2013-06-28 Grunenthal Gmbh Dosage form that is secured against misuse
DE10361596A1 (en) * 2003-12-24 2005-09-29 Grünenthal GmbH A process for preparing a secured against misuse dosage form
DE102004020220A1 (en) * 2004-04-22 2005-11-10 Grünenthal GmbH A process for preparing a secured against misuse, solid dosage form
SI1612203T1 (en) 2004-06-28 2007-12-31 Gruenenthal Chemie Crystalline forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
DE102004032103A1 (en) * 2004-07-01 2006-01-19 Grünenthal GmbH Abuse-proofed, oral dosage form
DE102004032049A1 (en) * 2004-07-01 2006-01-19 Grünenthal GmbH Abuse-proofed, oral dosage form
DE102004032051A1 (en) * 2004-07-01 2006-01-19 Grünenthal GmbH A process for preparing a secured against misuse, solid dosage form
AU2005259478B2 (en) * 2004-07-01 2010-07-15 Gruenenthal Gmbh Oral dosage form safeguarded against abuse containing (1R, 2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
DE102005005449A1 (en) * 2005-02-04 2006-08-10 Grünenthal GmbH A process for preparing a secured against misuse dosage form
DE102005005446A1 (en) * 2005-02-04 2006-08-10 Grünenthal GmbH Unbreakable dosage forms with delayed release
ES2358763T3 (en) * 2006-04-28 2011-05-13 Grünenthal GmbH pharmaceutical combination comprising 3- (3-dimethylamino-1-ethyl-2-methylpropyl) -phenol and an NSAID.
KR101396166B1 (en) 2006-04-28 2014-05-27 그뤼넨탈 게엠베하 Pharmaceutical combination comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and paracetamol
CN101091725A (en) * 2006-06-23 2007-12-26 天津天士力制药股份有限公司 Chinese traditional medicine grains and preparation method
SA2709B1 (en) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
DE102007011485A1 (en) * 2007-03-07 2008-09-11 Grünenthal GmbH Dosage form with impeded abuse
DE102007019417A1 (en) * 2007-04-23 2008-11-13 Grünenthal GmbH Tapentadol for treating pain in osteoarthritis
EP1985292A1 (en) * 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
NZ586361A (en) * 2007-11-23 2012-09-28 Gruenenthal Chemie Tapentadol compositions
CN101939287B (en) * 2007-12-07 2014-10-22 格吕伦塔尔有限公司 (1r, 2r) -3- (3- Dimethylamino-1-ethyl-2-methylpropyl) - - -phenol thereof
TWI454288B (en) * 2008-01-25 2014-10-01 Gruenenthal Chemie Pharmaceutical dosage form
CA2723438C (en) 2008-05-09 2016-10-11 Gruenenthal Gmbh Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
KR101806796B1 (en) 2008-10-30 2017-12-08 그뤼넨탈 게엠베하 Novel and potent tapentadol dosage forms
EP2456424B1 (en) 2009-07-22 2013-08-28 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form
PE10672012A1 (en) 2009-07-22 2012-09-05 Gruenenthal Chemie Form of controlled release dosage extruded by hot melt
CN102821757B (en) * 2010-02-03 2016-01-20 格吕伦塔尔有限公司 Preparation of a powdered pharmaceutical composition by an extruder
WO2011124953A2 (en) * 2010-04-07 2011-10-13 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
EP2566461A2 (en) * 2010-05-05 2013-03-13 Ratiopharm GmbH Solid tapentadol in non-crystalline form
CA2796774A1 (en) * 2010-06-15 2011-12-22 Gruenenthal Gmbh Pharmaceutical combination for the treatment of pain
AU2011273907B2 (en) 2010-06-30 2015-03-19 Grunenthal Gmbh Tapentadol for use in the treatment of Irritable Bowel Syndrome
CN103153971A (en) 2010-07-23 2013-06-12 格吕伦塔尔有限公司 Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
KR20130097202A (en) 2010-09-02 2013-09-02 그뤼넨탈 게엠베하 Tamper resistant dosage form comprising inorganic salt
JP5933553B2 (en) 2010-09-02 2016-06-15 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Abuse-resistant dosage form comprising an anionic polymer
BR112013022556A8 (en) 2011-03-04 2018-01-16 Gruenenthal Gmbh semisolid aqueous pharmaceutical composition containing tapentadol, their use and the use of tapentadol
BR112013022495A2 (en) 2011-03-04 2016-12-06 Grünenthal GmbH aqueous pharmaceutical formulation for oral administration of tapentadol
WO2012119728A1 (en) 2011-03-04 2012-09-13 Grünenthal GmbH Parenteral administration of tapentadol
EP2694049B1 (en) 2011-04-05 2018-10-31 Grünenthal GmbH Tapentadol for preventing chronification of pain
JP6040219B2 (en) 2011-04-05 2016-12-07 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Tapentadol for the treatment of pain associated with trigeminal neuropathic pain
WO2012146383A1 (en) 2011-04-29 2012-11-01 Grünenthal GmbH Tapentadol for preventing and treating depression and anxiety
HUE036567T2 (en) * 2011-07-29 2018-07-30 Gruenenthal Gmbh Intrathecal or epidural administration of 3-[(1s,2s)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol
HUE034711T2 (en) 2011-07-29 2018-02-28 Gruenenthal Gmbh Tamper-resistant tablet providing immediate drug release
EP2606879A1 (en) 2011-12-21 2013-06-26 Hexal AG Multiple unit pellet tablet formulation comprising an opioid
US20130225697A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CA2913209A1 (en) 2013-05-29 2014-12-04 Grunenthal Gmbh Tamper resistant dosage form with bimodal release profile
JP6445537B2 (en) 2013-05-29 2018-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Modified anti containing one or more particles (tamper-resistant) dosage forms
EP2808319A1 (en) 2013-05-31 2014-12-03 Arevipharma GmbH 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex
EP2845625A1 (en) 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
WO2015071248A1 (en) 2013-11-15 2015-05-21 Synthon B.V. Abuse-proofed extended release pharmaceutical composition comprising tapentadol
EP2942054A1 (en) * 2014-05-09 2015-11-11 G.L. Pharma GmbH Slow-release pharmaceutical formulation
JP2017518980A (en) 2014-05-12 2017-07-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Containing tapentadol, modified prevent immediate release capsule formulation
MX2016015417A (en) 2014-05-26 2017-02-22 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping.
TW201642843A (en) 2015-03-27 2016-12-16 Gruenenthal Gmbh Stable formulation for parenteral administration of Tapentadol
KR20170139158A (en) 2015-04-24 2017-12-18 그뤼넨탈 게엠베하 Immediately released and prevent the tamper-resistant dosage form extraction solvent
EP3231420A1 (en) 2016-02-29 2017-10-18 G.L. Pharma GmbH Abuse-deterrent pharmaceutical compositions
CA3037810A1 (en) 2016-09-23 2018-03-29 Grunenthal Gmbh Stable formulation for parenteral administration of tapentadol
WO2018153947A1 (en) 2017-02-23 2018-08-30 Grünenthal GmbH Tapentadol as local anesthetic

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
US4126672A (en) * 1976-02-04 1978-11-21 Hoffmann-La Roche Inc. Sustained release pharmaceutical capsules
US4389393B1 (en) * 1982-03-26 1985-10-22
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
SK281042B6 (en) * 1992-09-18 2000-11-07 Yamanouchi Pharmaceutical Co., Ltd Sustained-release hydrogel preparation
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
IL119660A (en) * 1993-05-10 2002-09-12 Euro Celtique Sa Controlled release formulation comprising tramadol
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
DE4329794C2 (en) * 1993-09-03 1997-09-18 Gruenenthal Gmbh Medicines containing tramadol sustained release
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
DE4426245A1 (en) * 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-phenyl-3-dimethylaminopropane compounds having pharmacological activity
US5478572A (en) 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
CN1125572A (en) 1994-12-28 1996-07-03 顺德市广容制药厂 Manufacture method of "Luotongding"pain-killing tablet
IL139728A (en) * 1995-01-09 2003-06-24 Penwest Pharmaceuticals Compan Aqueous slurry composition containing microcrystalline cellulose for preparing a pharmaceutical excipient
ES2322405T3 (en) * 1996-07-08 2009-06-19 Penwest Pharmaceuticals Co. Matrix controlled to high doses insoluble drugs release.
DE19630035A1 (en) * 1996-07-25 1998-01-29 Asta Medica Ag Tramadol multiple unit formulations
AT302597T (en) * 1997-06-06 2005-09-15 Depomed Inc In the stomach, lingering oral dosage forms of water-soluble drugs with controlled release
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6106862A (en) * 1998-08-13 2000-08-22 Andrx Corporation Once daily analgesic tablet
AU764453B2 (en) * 1999-10-29 2003-08-21 Euro-Celtique S.A. Controlled release hydrocodone formulations

Also Published As

Publication number Publication date
NO2012007I2 (en) 2013-01-02
EP1439829B1 (en) 2005-09-07
MXPA04003742A (en) 2004-07-23
JP4758064B2 (en) 2011-08-24
US20160151309A1 (en) 2016-06-02
IL161587D0 (en) 2004-09-27
SI1439829T1 (en) 2006-02-28
HK1068539A1 (en) 2006-04-21
CO5570662A2 (en) 2005-10-31
DE50204198D1 (en) 2005-10-13
EP1439829A1 (en) 2004-07-28
NO20041924L (en) 2004-05-11
PL369756A1 (en) 2005-05-02
PL216535B1 (en) 2014-04-30
DK1439829T3 (en) 2005-10-10
ECSP045102A (en) 2004-06-28
US20130237608A1 (en) 2013-09-12
WO2003035053A1 (en) 2003-05-01
US20050058706A1 (en) 2005-03-17
JP2005506367A (en) 2005-03-03
KR20040047964A (en) 2004-06-05
NO331896B1 (en) 2012-04-30
IL161587A (en) 2009-12-24
JP2010280697A (en) 2010-12-16
ES2248622T3 (en) 2006-03-16
BR0213653A (en) 2004-10-26
ZA200403928B (en) 2005-07-27
CN1607947A (en) 2005-04-20
HU230161B1 (en) 2015-09-28
CN100402021C (en) 2008-07-16
AR036943A1 (en) 2004-10-13
MY127797A (en) 2006-12-29
CA2464578C (en) 2011-10-11
US20120034304A1 (en) 2012-02-09
NO2012007I1 (en) 2012-05-21
US20180221308A1 (en) 2018-08-09
US20170087103A1 (en) 2017-03-30
WO2003035054A1 (en) 2003-05-01
NZ532999A (en) 2007-06-29
AT303802T (en) 2005-09-15
KR100958045B1 (en) 2010-05-17
HU0402104A2 (en) 2005-03-29
CA2464578A1 (en) 2003-05-01
PT1439829E (en) 2005-11-30

Similar Documents

Publication Publication Date Title
Bockbrader et al. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin
Clausen et al. In vitro evaluation of the permeation‐enhancing effect of thiolated polycarbophil
ES2525497T3 (en) controlled release pharmaceutical compositions comprising fumaric acid ester
Holzhausen et al. Effect of selective cyclooxygenase‐2 inhibition on the development of ligature‐induced periodontitis in rats
Mailly et al. Increase in external glutamate and NMDA receptor activation contribute to H2O2‐induced neuronal apoptosis
ES2496144T3 (en) Capsule Formulation pirfenidone and pharmaceutically acceptable excipients
ES2248622T3 (en) Medicament containing 3- (3-dimethylamino-1-ethyl-2-methylpropyl) -phenol and provides a delayed release of the active ingredient.
Schmidt et al. What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs?
Jin et al. Fluoxetine attenuates kainic acid-induced neuronal cell death in the mouse hippocampus
ES2582646T3 (en) Coated tablet formulation and method
Elliott et al. A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats
RU2396980C2 (en) Method of treating lupous
Hutchings et al. Plasma concentrations of delta-9-tetrahydrocannabinol in dams and fetuses following acute or multiple prenatal dosing in rats
Berk Lamotrigine and the treatment of mania in bipolar disorder
Yip et al. Sesquiterpene lactone parthenolide blocks lipopolysaccharide‐induced osteolysis through the suppression of NF‐κB activity
NO333572B1 (en) Ropinirolholdig hydrophilic / lipophilic polymer matriksdoseringsformulering
BRPI0710826A2 (en) Pharmaceutical compositions antagonist anti-CD40 antibody
NO20074412L (en) Fracture resistant administration forms with delayed release
AT458486T (en) Solid, orally administrable pharmaceutical dosage forms comprising modified release rivaroxaban
AR039379A1 (en) Matrix for sustained, invariant and independent release of active compounds
CR9842A (en) Celecoxib compositions
UY27796A1 (en) pharmaceutical formulations
BRPI0409250A (en) Solid pharmaceutical compositions comprising a S1P receptor agonist and a sugar alcohol
ECSP066346A (en) Method of administration proof of abuse
ECSP066345A (en) Method of administration proof of abuse

Legal Events

Date Code Title Description
FC Refusal
AE Restoration of lapsed or forfeited application
FG Grant, registration